Selectivity of SSRIs: individualising patient care through rational treatment choices

REFERENCES

• Fichter M, Leibl K, Rief W et al (1991) Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry 24: 107.
   Google Scholar
• Zohar J, Wetenberg H (2000) Anxiety disorders: a review of tricyclic antidepressants and selective serotonin re-uptake inhibitors. Acta Psychiatr Scand Suppl 403: 39–49.
   PubMedGoogle Scholar
• Pigott T, Seay S (1999) A review of the efficacy of selective serotonin re-uptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatr 60: 101–6.
   PubMed Web of Science ®Google Scholar
• Dimmock P, Wyatt K, Jones P et al (2000) Efficacy of selective serotonin re-uptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356: 1131–6.
   Google Scholar
• van der Linden G, Stein D, van Balkom A (2000) The efficacy of the selective serotonin re-uptake inhibitors for social anxiety disorder (social phobia); a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 15: 515–23.
   Google Scholar
• Clemmesen L (1988) Anticholinergic side-effects of antidepressants: studies of the inhibition of salivation. Acta Psychiatr Scand Suppl 345: 90–3.
   PubMedGoogle Scholar
• Beaumont G (1988) Adverse effects of tricyclic and non-tricyclic antidepressants. Int Clin Psychopharmacol 3 (Suppl. 2): 55–61.
   Google Scholar
• Feighner J, Boyer W (1996) Selective serotonin re-uptake inhibitors, Advances in Basic Research and Clinical Practice (2nd Edn). Wiley, Chichester.
   Google Scholar
• Stahl S (1996) Essential Psychopharmacology. New York: Cambridge University Press.
   Google Scholar
• Barker E, Blakely R (1995) Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. In:Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. New York: Raven Press: 321–34.
   Google Scholar
• Stahl S (1998) Mechanism of action of serotonin selective re- uptake inhibitors. Serotonin receptors and pathways mediate therapeutics effects and side-effects. J Affect Disord 51: 215–35.
   PubMed Web of Science ®Google Scholar
• Stahl S (2000) Essential psychopharmacology (2nd Edn) Cambridge University Press, New York.
   Google Scholar
• Brown S, van Praag H (1991) The role of serotonin in psychiatric disorders. Brunner/Mazel, New York.
   Google Scholar
• Cowen P (1991) Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatry 159: 7–14.
   PubMed Web of Science ®Google Scholar
• Glennon R, Dukat M (1995) Serotonin receptor subtypes. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. New York: Raven Press: 415–30.
   Google Scholar
• Kunovac J, Stahl S (1995) Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. Int Rev Psychiatry 7: 55–68.
   Web of Science ®Google Scholar
• Shih J, Chen K, Gallaher T (1995) Molecular biology of serotonin receptors: a basis for understanding and addressing brain function. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. New York: Raven Press: 407–14.
   Google Scholar
• Jacobs B, Fornal C (1995) Serotonin and behavior: a general hypothesis. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. New York: Raven Press: 461–70.
   Google Scholar
• Langer S, Brunello N, Racagni G, Mendlewicz J (1992) Serotonin receptor subtypes: pharmacological significance and clinical implications. Karger, Basel.
   Google Scholar
• Frazer A, Maayani S, Wolfe B (1990) Subtypes of receptors for serotonin. Annu Rev Pharmacol Toxicol 30: 307–48.
   PubMed Web of Science ®Google Scholar
• Hoyer D, Clarke D, Fozard J et al (1994) International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46: 157–203.
   Google Scholar
• Thase M, Feighner J, Lydiard R (2001) Citalopram treatment of fluoxetine nonresponders. J Clin Psychiatry 62: 683–7.
   PubMed Web of Science ®Google Scholar
• Benfield P, Ward A (1986) Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 32: 313–4.
   PubMed Web of Science ®Google Scholar
• Benfield P, Heel R, Lewis S (1986) Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 32: 482–508.
   Web of Science ®Google Scholar
• Dechant K, Clissold S (1991) Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs 41: 225–53.
   PubMed Web of Science ®Google Scholar
• Murdoch D, McTavish D (1992) Sertraline: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 44: 604–24.
   PubMed Web of Science ®Google Scholar
• Owens M, Knight D, Nemeroff C (2001) Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50: 345 -50.
   Web of Science ®Google Scholar
• Sa´nchez C, Larsen A, Brennum L et al (2002) Escitalopram, an extremely selective serotonin re-uptake inhibitor. Int J Neuropsychopharmacol 59 (Suppl. 1): S66.
   Google Scholar
• Schmidt K, Nolte-Zenker B, Patzer J et al (2001) Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Pharmacopsychiatry 34: 66–72.
   Google Scholar
• Stahl S (1998) Using secondary binding properties to select a not so selective serotonin re-uptake inhibitor. J Clin Psychiatry 59: 642–3.
   PubMed Web of Science ®Google Scholar
• Judge R, Plewes J, Kumar V et al (2000) Changes in energy during treatment of depression: an analysis of fluoxetine in double-blind, placebo-controlled trials. J Clin Psychpharmacol 20: 666–72.
   Google Scholar
• Stokes P, Holtz A (1997) Fluoxetine Tenth Anniversary Update: The Progress Continues. Clin Ther 19: 1135–50.
   PubMed Web of Science ®Google Scholar
• Tulloch I, Lowther S, Crompton M et al (1995) Pharmacological differences between selective serotonin re-uptake inhibitors: interaction with 5-HT and sigma binding sites in human brain in vitro. Eur Neuropsychopharmacol 5 (Suppl. 3): 281.
   Google Scholar
• Bolden-Watson C, Richelson E (1993) Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52: 1023–9.
   PubMed Web of Science ®Google Scholar
• Edwards J, Anderson I (1999) Systematic review and guide to selection of selective serotonin re-uptake inhibitors. Drugs 57: 507–33.
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum J, Hoog S et al (2000) Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 59: 119–26.
   Google Scholar
• Sechter D, Troy S, Paternetti S, Boyer P (1999) A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 14: 41–8.
   PubMed Web of Science ®Google Scholar
• Sogaard J, Lane R, Latimer P et al (1999) A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 13: 406–14.
   Google Scholar
• Finkel S, Richter E, Clary C (1999) Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. Int Psychogeriatr 11: 85–99.
   PubMedGoogle Scholar
• Newhouse P (1996) Use of serotonin selective re-uptake inhibitors in geriatric depression. J Clin Psychiatry 57 (Suppl. 5): 12 -22.
   Google Scholar
• Aguglia E, Casacchia M, Cassano G et al (1993) Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 8: 197–202.
   Google Scholar
• Flament MF, Lane RM, Zhu R, Ying Z (1999) Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol 14: 259–75.
   PubMed Web of Science ®Google Scholar
• Zimmerman M, McDemut W, Mattia J (2000) Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am J Psychiatry 157: 1337–40.
   PubMed Web of Science ®Google Scholar
• Rouillon F (1999) Anxiety with depression: a treatment need. Eur Neuropsychopharmacol 9: S87 -92.
   PubMed Web of Science ®Google Scholar
• Boerner R, Mo¨ ller H (1999) The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry 32: 119–26.
   Google Scholar
• Joubert A, Stein D (1999) Citalopram and anxiety disorders. Rev Contemp Pharmacother 10: 79–123.
   Web of Science ®Google Scholar
• Tye N, Iversen S, Green A (1979) The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 18: 689–95.
   PubMed Web of Science ®Google Scholar
• Stein L, Wise C, Belluzi J (1975) Effects of benzodiazepines on central serotonergic mechanisms. In: Costa E, Greengard P (eds) Mechansim of benzodiazepines. New York: Raven Press: 29–44.
   Google Scholar
• Barrett J, Vanover K (1993) 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmacology (Berlin) 112: 1–12.
   PubMed Web of Science ®Google Scholar
• Schreiber R, Melon C, De Vry J (1998) The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin re-uptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology (Berlin) 135: 383–91.
   PubMed Web of Science ®Google Scholar
• Sa´ nchez C, Meier E (1997) Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berlin) 129: 197–205.
   Google Scholar
• Ballenger J (1996) Selective serotonin re-uptake inhibitors in panic disorder. In: Feighner J, Boyer W (eds) Selective serotonin re- uptake inhibitors, Advances in Basic Research and Clinical practice, 2nd Edn. Wiley: Chichester: 155–78.
   Google Scholar
• Pollock BG, Mulsant BH, Nebes R et al (1998) Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry 155: 1110–2.
   Google Scholar
• Dunbar G (1989) An interim overview of the safety and tolerability of paroxetine. Acta Psychiatr Scand Suppl 80 (350): 135–7.
   Google Scholar
• Kiev A, Feiger A (1997) A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58: 146–52.
   PubMed Web of Science ®Google Scholar
• Aberg-Wistedt A, Agren H, Ekselius L et al (2000) Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 20: 645–52.
   Google Scholar
• Narita H, Hashimoto K, Tomitaka S, Minabe Y (1996) Interactions of selective serotonin re-uptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307: 117–9.
   PubMed Web of Science ®Google Scholar
• Su T, Hayashi T (2003) Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 10: 2073–80.
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Gasperini M et al (1996) Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 153: 1631–3.
   Google Scholar
• Gatti F, Bellini L, Gasperini M et al (1996) Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 153: 414–6.
   Google Scholar
• Sa´nchez C, Bergqvist P, Brennum L et al (2003) Escitalopram, the S-(+) enantiomer of citalopram is a selective serotonin re-uptake inhibitor with potent effects of animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167: 353–62.
   Google Scholar
• Drewes P, Thijssen I, Mengel H (2001) A single-dose cross-over pharmacokinetic study comparing racemic citalopram (40mg) with the S-enantiomer of citalopram (escitalopram, 20mg) in healthy male volunteers. Poster presented at the 41st Annual Meeting of the New Clinical Data Evaluation Unit (NCDEU), Phoenix, AZ, USA, 29 May -1 June 2001. Abstract available at http://www.nimh.nih.gov/ncdeu/abstracts2001/ncdeu2045.csm.
   Google Scholar
• Wade A (2002) Long-term treatment of depression with escitalopram is safe and well-tolerated. Int J Neuropsychophar- macol 5 (Suppl 1): S146.
   Google Scholar
• Boyer W, Feighner J (1996) Other uses of selective serotonin re- uptake inhibitors in psychiatry. In Feighner J, Boyer W, Selective serotonin re-uptake inhibitors: advances in basic research and clinical practice (2nd Edn). Wiley: Chichester: 291–314.
   Google Scholar
• Stein D, Hollander E (1994) Sexual dysfunction associated with the drug treatment of psychiatric disoders. CNS Drugs 2: 78–86.
   Web of Science ®Google Scholar
• Montejo-Gonzalez A, Liorca G, Izquierdo J et al (1997) SSRI- induced sexual dysfunction: fluoxetine, paroxetine, sertraline and fluvoxamine in a prospective, multicenter and descriptive clinical study of 344 patients. J Sex Marital Ther 23: 176–94.
   Google Scholar
• Angulo J, Peiro C, Sanchez-Ferrer C et al (2001) Differential effects of serotonin reuptake inhibitors on erectile responses, NO- production, and neuronal NO synthase expression in rat corpus cavernosum tissue. Br J Pharmacol 134: 1190–4.
   Google Scholar
• Balon R (1996) Antidepressants in the treatment of premature ejaculation. J Sex Marital Ther 22: 85–96.
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Semercioz A (2002) The efficacy of citalopram in the treatment of premature ejaculation: a placebo- controlled study. Int J Impot Res 14: 502–5.
   PubMed Web of Science ®Google Scholar
• Waldinger M, Zwinderman A, Olivier B (2001) SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol 21: 556–60.
   PubMed Web of Science ®Google Scholar
• Harvey A, Preskorn S (1996) Cytochrome P450 enzymes: interpretations of their interactions with selective serotonin re- uptake inhibitors. Part 1. J Clin Psychopharmacol 16: 273–85.
   PubMed Web of Science ®Google Scholar
• Wang J, Liu Z, Wang W et al (2001) Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 70: 42–7.
   Google Scholar
• Keppel Hesselink J, Sambunaris A (1995) Behavioral pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. Int Rev Psychiatry 7: 41–54.
   Web of Science ®Google Scholar
• Cliffe I, Fletcher A (1993) Advances in 5-HT1A antagonist research. Drugs Future 18: 631–42.
   Google Scholar
• Dubovsky S (1994) Beyond the serotonin re-uptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 55: 34–44.
   PubMed Web of Science ®Google Scholar
• Stahl S (1992) Serotonin 1A receptors in depression and anxiety. New York, Raven Press: 55–82.
   Google Scholar
• Bersani G, Grispini A, Marini S et al (1990) 5-HT2 antagonist ritanserin in neuroleptic induced parkinsonism: a double blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13: 500–6.
   Google Scholar
• Leysen J (1992) 5-HT2 receptors: location, pharmacological pathological and physiological role. In: Langer S, Brunello N, Racagni G, Mendlewicz J (eds) Serotonin receptor subtypes: pharmacological significance and clinical implications. Basel: Karger: 31–44.
   Google Scholar
• Trickelbank M (1989) Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 10: 127–9.
   PubMed Web of Science ®Google Scholar
• Bunce K, Tyers M, Beranek P (1991) Clinical evaluation of 5-HT3 receptor agonists as antiemetics. Trends Pharmacol Sci 12: 46–8.
   PubMed Web of Science ®Google Scholar
• Levitt M, Warr D, Yelle L (1993) Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemptherapy of breast cancer with cyclophosphamide, methotrexate and flurouracil. New Engl J Med 328: 1081–4.
   PubMed Web of Science ®Google Scholar
• Waugh J, Goa K (2003) Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 17: 985–92.
   PubMed Web of Science ®Google Scholar